Pasar al contenido principal

MECANISMOS CELULARES Y MOLECULARES IMPLICADOS EN EL EFECTO CARDIOPROTECTOR DE LA VITAMINA D

SAF2014-57190-R

•
Nombre agencia financiadora Ministerio de Economía y Competitividad
Acrónimo agencia financiadora MINECO
Programa Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Convocatoria Proyectos I+D+i Retos de Investigación
Año convocatoria 2014
Plan Estatal 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Unidad de gestión Secretaría de Estado de Educación, Formación Profesional y Universidades
Centro beneficiario AGENCIA ESTATAL CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC)
Identificador persistente http://dx.doi.org/10.13039/501100003329

Resultados relacionados

Resultados totales (Incluyendo duplicados): 8
Encontrada(s) 1 página(s)

DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Role of NOD1 in heart failure progression via regulation of Ca2+ handling

  • Val-Blasco, Almudena
  • Ruiz-Hurtado, Gema
  • Prieto, Patricia
  • González-Ramos, Silvia
  • Gómez-Hurtado, Nieves
  • Delgado, Carmen
  • Benito, Gemma
  • Zaragoza, Carlos
  • López-Collazo, Eduardo
  • Boscá, Lisardo
  • Fernández-Velasco, María
[Background]: Heart failure (HF) is a complex syndrome associated with a maladaptive innate immune system response that leads to deleterious cardiac remodeling. However, the underlying mechanisms of this syndrome are poorly understood. Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is a newly recognized innate immune sensor involved in cardiovascular diseases. [Objectives]: This study evaluated the role of NOD1 in HF progression. [Methods]: NOD1 was examined in human failing myocardium and in a post-myocardial infarction (PMI) HF model evaluated in wild-type (wt-PMI) and Nod1 mice (Nod1-PMI). [Results]: The NOD1 pathway was up-regulated in human and murine failing myocardia. Compared with wt-PMI, hearts from Nod1-PMI mice had better cardiac function and attenuated structural remodeling. Ameliorated cardiac function in Nod1-PMI mice was associated with prevention of Ca dynamic impairment linked to HF, including smaller and longer intracellular Ca concentration transients and a lesser sarcoplasmic reticulum Ca load due to a down-regulation of the sarcoplasmic reticulum Ca-adenosine triphosphatase pump and by augmented levels of the Na/Ca exchanger. Increased diastolic Ca release in wt-PMI cardiomyocytes was related to hyperphosphorylation of ryanodine receptors, which was blunted in Nod1-PMI cardiomyocytes. Pharmacological blockade of NOD1 also prevented Ca mishandling in wt-PMI mice. Nod1-PMI mice showed significantly fewer ventricular arrhythmias and lower mortality after isoproterenol administration. These effects were associated with lower aberrant systolic Ca release and with a prevention of the hyperphosphorylation of ryanodine receptors under isoproterenol administration in Nod1-PMI mice. [Conclusions]: NOD1 modulated intracellular Ca mishandling in HF, emerging as a new target for HF therapy., This work was supported by grants CP11/00080 and PI14/01078 from Instituto de Salud Carlos III (ISCIII); SAF2014-52492-R, SAF2014-57190-R, and RTC2015-3741 from Ministerio de Economía y Competitividad; Fondos Fondo Europeo de Desarrollo Regional; and Red de Investigación Cardiovascular (RIC) RD12/0042/0019. RIC is a network funded by the Carlos III Health Institute. Dr. Fernández Velasco is Miguel Servet researcher of ISCIII., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial effects of leptin treatment in a setting of cardiac dysfunction induced by transverse aortic constriction in mouse

  • Gómez-Hurtado, Nieves
  • Domínguez-Rodríguez, Alejandro
  • Mateo, Philippe
  • Fernández-Velasco, María
  • Val-Blasco, Almudena
  • Aizpún, Rafael
  • Sabourin, Jessica
  • Gómez, Ana María
  • Benitah, Jean-Pierre
  • Delgado, Carmen
Leptin, is a 16 kDa pleiotropic peptide not only primary secreted by adipocytes, but also produced by other tissues, including the heart. Evidence indicates that leptin may have either adverse or beneficial effects on the heart. To obtain further insights, in the present study, we analysed the effect of leptin treatment on cardiac function, [Ca2+]i handling and cellular electrophysiology, which participate in the genesis of pump failure and related arrhythmias, both in control mice and in mice subjected to chronic pressure‐overload by transverse aorta constriction (TAC). Three weeks after surgery, animals received either leptin (0.36 mg kg–1 day–1) or vehicle via osmotic minipumps for 3 weeks. Echocardiographic measurements showed that, although leptin treatment was deleterious on cardiac function in sham, leptin had a cardioprotective effect following TAC. [Ca2+]i transient in cardiomyocytes followed similar pattern. Patch clamp experiments showed prolongation of action potential duration (APD) in TAC and leptin‐treated sham animals, whereas, following TAC, leptin reduced the APD towards control values. APD variations were associated with decreased transient outward potassium current and Kv4.2 and KChIP2 protein expression. TAC myocytes showed a higher incidence of triggered activities and spontaneous Ca2+ waves. These proarrhythmic manifestations, related to Ca2+/calmodulin‐dependent protein kinase II and ryanodine receptor phosphorylation, were reduced by leptin. The results of the present study demonstrate that, although leptin treatment was deleterious on cardiac function in control animals, leptin had a cardioprotective effect following TAC, normalizing cardiac function and reducing arrhythmogeneity at the cellular level., SAF‐2010‐16377 and SAF2014‐57190R from Ministerio de Economía y Competitividad (MINECO); Agence Nationale de la Recherche (ANR‐13‐BSV1‐0023‐01 and ANR‐15‐CE14‐0005); Fondation pour la recherche médicale (Programme cardiovasculaire 2011); CORDDIM‐Région Ile de France (Équipement jeune équipe 2010; Petit et moyen équipement 2011); ISCIII PI14/01078 and Fondos Feder. The laboratory UMR‐S 1180 is a member of the Laboratory of Excellence LERMIT supported by a grant from the Agence Nationale de la Recherche (ANR‐10‐LABX‐33). NGH was a FPU fellow of the Spanish Ministry of Education., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Calcitriol, the bioactive metabolite of vitamin D, increases ventricular K+ currents in isolated mouse cardiomyocytes

  • Tamayo, María
  • Martín-Nunes, Laura
  • Val-Blasco, Almudena
  • Piedras, Maria J.
  • Larriba, María Jesús
  • Gómez-Hurtado, Nieves
  • Fernández-Velasco, María
  • Delgado, Carmen
Calcitriol, the bioactive metabolite of vitamin D, interacts with the ubiquitously expressed nuclear vitamin D receptor (VDR) to induce genomic effects, but it can also elicit rapid responses via membrane-associated VDR through mechanisms that are poorly understood. The down-regulation of K+ currents is the main origin of electrophysiological remodeling in pathological hypertrophy and heart failure (HF), which can contribute to action potential prolongation and subsequently increase the risk of triggered arrhythmias. Adult mouse ventricular myocytes were isolated and treated with 10 nM calcitriol or vehicle for 15-30 min. In some experiments, cardiomyocytes were pretreated with the Akt inhibitor triciribine. In the adult mouse ventricle, outward K+ currents involved in cardiac repolarization are comprised of three components: the fast transient outward current (Itof), the ultrarapid delayed rectifier K+ current (Ikur), and the non-inactivating steady-state outward current (Iss). K+ currents were investigated using the whole-cell or the perforated patch-clamp technique and normalized to cell capacitance to obtain current densities. Calcitriol treatment of cardiomyocytes induced an increase in the density of Itof and Ikur, which was lost in myocytes isolated from VDR-knockout mice. In addition, calcitriol activated Akt in cardiomyocytes and pretreatment with triciribine prevented the calcitriol-induced increase of outward K+ currents. In conclusion, we demonstrate that calcitriol via VDR and Akt increases both Itof and Ikur densities in mouse ventricular cardiomyocytes. Our findings may provide new mechanistics clues for the cardioprotective role of this hormone in the heart., This work was supported by grants SAF2014-57190R, SAF2017-84777R, and SAF2016-76377R from the Spanish Ministerio de Industria, Economia y Competitividad and PI14/01078 and PI17/01344 from ISCIII, Fondos FEDER and CIBER-CV and CIBERONC, networks funded by ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Deficiency of NOD1 improves the β-adrenergic modulation of Ca2+ handling in a mouse model of heart failure

  • Val-Blasco, Almudena
  • Navarro-García, Jose A.
  • Tamayo, María
  • Piedras, Maria J.
  • Prieto, Patricia
  • Delgado, Carmen
  • Ruiz-Hurtado, Gema
  • Rozas-Romero, Laura
  • Gil-Fernández, Marta
  • Zaragoza, Carlos
  • Boscá, Lisardo
  • Fernández-Velasco, María
Heart failure (HF) is a complex syndrome characterized by cardiac dysfunction, Ca2+ mishandling, and chronic activation of the innate immune system. Reduced cardiac output in HF leads to compensatory mechanisms via activation of the adrenergic nervous system. In turn, chronic adrenergic overstimulation induces pro-arrhythmic events, increasing the rate of sudden death in failing patients. Nucleotide-binding oligomerization domain-containing protein 1 (NOD1) is an innate immune modulator that plays a key role in HF progression. NOD1 deficiency in mice prevents Ca2+ mishandling in HF under basal conditions, but its role during β-adrenergic stimulation remains unknown. Here, we evaluated whether NOD1 regulates the β-adrenergic modulation of Ca2+ signaling in HF. Ca2+ dynamics were examined before and after isoproterenol perfusion in cardiomyocytes isolated from healthy and from post-myocardial infarction (PMI) wild-type (WT) and Nod1-/- mice. Isoproterenol administration induced similar effects on intracellular [Ca2+]i transients, cell contraction, and sarcoplasmic reticulum (SR)-Ca2+ load in healthy WT and Nod1-/- cells. However, compared with WT-PMI cells, isoproterenol exposure induced a significant increase in the [Ca2+]i transients and cell contraction parameters in Nod1-/--PMI cells, which mainly due to an increase in SR-Ca2+ load. NOD1 deficiency also prevented the increase in diastolic Ca2+ leak (Ca2+ waves) induced by isoproterenol in PMI cells. mRNA levels of β1 and β2 adrenergic receptors were significantly higher in Nod1-/--PMI hearts vs WT-PMI hearts. Healthy cardiomyocytes pre-treated with the selective agonist of NOD1, iE-DAP, and perfused with isoproterenol showed diminished [Ca2+]i transients amplitude, cell contraction, and SR-Ca2+ load compared with vehicle-treated cells. iE-DAP-treated cells also presented increased diastolic Ca2+ leak under β-adrenergic stimulation. The selectivity of iE-DAP on Ca2+ handling was validated by pre-treatment with the inactive analog of NOD1, iE-Lys. Overall, our data establish that NOD1 deficiency improves the β-adrenergic modulation of Ca2+ handling in failing hearts., MF-V is Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). This work was supported by grants PI14/01078, CP15/00129, PI17/01093, and PI17/01344 from ISCIII, Fondo Europeo de Desarrollo Regional (FEDER Ministerio de Economía y Competitividad of Spain (SAF2014-57190-R; SAF2017-84777-R), FSE, and CIBER-CV, a network funded by ISCIII., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

PTH, vitamin D, and the FGF-23–klotho axis and heart: Going beyond the confines of nephrology

  • Navarro-García, Jose A.
  • Fernández-Velasco, María
  • Delgado, Carmen
  • Delgado, Juan F.
  • Kuro-o, Makoto
  • Ruilope, Luis M.
  • Ruiz-Hurtado, Gema
[Background]: Profound disturbances in mineral metabolism are closely linked to the progression of chronic kidney disease. However, increasing clinical and experimental evidence indicates that alterations in phosphate homoeostasis could have an even stronger impact on the heart., [Aim]: The aim of this review is to provide the reader with an update of how alterations in mineral metabolism are related to direct and indirect cardiotoxic effects beyond the nephrology setting., [Results]: Evidence exists that alterations in mineral metabolism that are related to changes in parathyroid hormone (PTH), vitamin D, and the FGF‐23–klotho axis have direct pathological consequences for the heart. Alterations in plasma PTH levels are associated with cardiac dysfunction and detrimental cardiac remodelling. Several clinical studies have associated vitamin D deficiency with the prevalence of cardiovascular disease (CV) and its risk factors. Recent evidences support deleterious direct and nonphosphaturic effects of FGF‐23 on the heart as hypertrophy development. In contrast, reduced systemic klotho levels are related to CV damage, at least when advanced age is present. In addition, we discuss how these mineral metabolism molecules can counteract each other in some situations, in the context of failed clinical trials on cardiac protection as is the case of vitamin D supplementation., [Conclusions]: Among all mineral components, an increase in systemic FGF‐23 levels is considered to have the greatest CV impact and risk. However, it is quite possible that many intracellular mechanisms mediated by FGF‐23, especially those related to cardiomyocyte function, remain to be discovered., The authors acknowledge the support from the Spanish Institute of Health, Carlos III (PIE13/00045, PI14/01841, PI14/01078, CP15/00129, MSII16/00047, PI17/01093, PI17/01193, PI17/01344), Ministerio de Economía Industria y Competitividad (SAF‐2014‐57190R), Fundación SENEFRO/Sociedad Española de Nefrología (SEN), Sociedad Española de Cardiología (SEC), Fundación Íñigo Álvarez de Toledo (FRIAT) and CIBER de Enfermedades Cardiovasculares (CIBERCV) and Fondos FEDER., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Contribución de congreso (ConferenceOutput)

Beneficial effects of paricalcitol on cardiac dysfunction and deleterious remodeling after established heart failure

  • Delgado, Carmen
  • Tamayo, María
  • Martin-Hijano, Laura
  • Val-Blasco, Almudena
  • García-Piedras, María José
  • Navarro-García, Jose A.
  • Lage, Eduardo
  • Prieto, Patricia
  • Ruiz-Hurtado, Gema
  • Fernández-Velasco, María
Resumen del trabajo presentado al VII Congreso Red Española Canales Iónicos: Symposium 3: Calcium signaling and Cell Function, celebrado en Cáceres del 15 al 17 de mayo de 2019., Supported by SAF2014-57190R; Spanish Society of Cardiology (SEC) and FPU17/06135., Peer Reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Fibroblast growth factor-23 promotes rhythm alterations and contractile dysfunction in adult ventricular cardiomyocytes

  • Navarro-García, Jose A.
  • Delgado, Carmen
  • Fernández-Velasco, María
  • Val-Blasco, Almudena
  • Rodríguez-Sánchez, Elena
  • Aceves‑Ripoll, Jennifer
  • Gómez-Hurtado, Nieves
  • Bada-Bosch, Teresa
  • Mérida-Herrero, Evangelina
  • Hernández, Eduardo
  • Praga, Manuel
  • Salguero, Rafael
  • Solís, Jorge
  • Arribas, Fernando
  • Delgado, Juan F.
  • Bueno, Héctor
  • Kuro-o, Makoto
  • Ruilope, Luis M.
  • Ruiz-Hurtado, Gema
[Background]: Cardiac dysfunction and arrhythmia are common and onerous cardiovascular events in end-stage renal disease (ESRD) patients, especially those on dialysis. Fibroblast growth factor (FGF)-23 is a phosphate-regulating hormone whose levels dramatically increase as renal function declines. Beyond its role in phosphorus homeostasis, FGF-23 may elicit a direct effect on the heart. Whether FGF-23 modulates ventricular cardiac rhythm is unknown, prompting us to study its role on excitation–contraction (EC) coupling., [Methods]: We examined FGF-23 in vitro actions on EC coupling in adult rat native ventricular cardiomyocytes using patch clamp and confocal microscopy and in vivo actions on cardiac rhythm using electrocardiogram., [Results]: Compared with vehicle treatment, FGF-23 induced a significant decrease in rat cardiomyocyte contraction, L-type Ca2+ current, systolic Ca2+ transients and sarcoplasmic reticulum (SR) load and SR Ca2+-adenosine triphosphatase 2a pump activity. FGF-23 induced pro-arrhythmogenic activity in vitro and in vivo as automatic cardiomyocyte extracontractions and premature ventricular contractions. Diastolic spontaneous Ca2+ leak (sparks and waves) was significantly increased by FGF-23 via the calmodulin kinase type II (CaMKII)-dependent pathway related to hyperphosphorylation of ryanodine receptors at the CaMKII site Ser2814. Both contraction dysfunction and spontaneous pro-arrhythmic Ca2+ events induced by FGF-23 were blocked by soluble Klotho (sKlotho)., [Conclusions]: Our results show that FGF-23 reduces contractility and enhances arrhythmogenicity through intracellular Ca2+ mishandling. Blocking its actions on the heart by improving sKlotho bioavailability may enhance cardiac function and reduce arrhythmic events frequently observed in ESRD., This work was supported by grants from the Spanish Institute of Health Carlos III (PIE13/00045, PI14/01841, CP15/00129, PI17/01093, PI17/01193, PI14/01078, PI17/01344, MSII16/00047), Fundación SENEFRO/Sociedad Española de Nefrología (SEN), Sociedad Española de Cardiología (SEC), Luis Hernando Project from Fundación Íñigo Álvarez de Toledo (FRIAT) and Fondo Europeo de Desarrollo Regional (Fondos FEDER) and Ministerio de Economía, Industria y Competitividad (SAF2014-57190-R, SAF2017-84777-R). Jennifer Aceves-Ripoll was funded by Comunidad de Madrid [Programa Operativo de Empleo Juvenil y la Iniciativa de Empleo Juvenil (YEI) 2015]., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publicación Artículo científico (JournalArticle)

Beneficial effects of paricalcitol on cardiac dysfunction and remodelling in a model of established heart failure

  • Tamayo, María
  • Martín-Nunes, Laura
  • Val-Blasco, Almudena
  • Piedras, Maria J.
  • Navarro-García, Jose A.
  • Lage, Eduardo
  • Prieto, Patricia
  • Ruiz-Hurtado, Gema
  • Fernández-Velasco, María
  • Delgado, Carmen
[Background and Purpose]: The synthetic vitamin D3 analogue paricalcitol acts as a selective activator of the vitamin D receptor (VDR). While there is evidence for cardioprotective effects of paricalcitol associated with the VDR pathway, less information is available about the structural and functional cardiac effects of paricalcitol on established heart failure (HF) and particularly its effects on associated electrophysiological or Ca2+ handling remodelling., [Experimental Approach]: We used a murine model of transverse aortic constriction (TAC) to study the effect of paricalcitol on established HF. Treatment was initiated 4 weeks after surgery over five consecutive weeks, and mice were sacrificed 9 weeks after surgery. Cardiac MRI (CMRI) was performed 4 and 9 weeks after surgery. Hearts were used for biochemical and histological studies and to isolate ventricular myocytes for electrophysiological and calcium imaging studies., [Key Results]: CMRI analysis revealed that, compared with vehicle, paricalcitol treatment prevented the progression of ventricular dilation and hypertrophy after TAC and halted the corresponding decline in ejection fraction. These beneficial effects were related to the attenuation of intracellular Ca2+ mishandling remodelling, antifibrotic and antihypertrophic effects and potentially antiarrhythmic effects by preventing the reduction of K+ current density and the long QT, JT and TpTe intervals observed in HF animals., [Conclusion and Implications]: The results suggest that paricalcitol treatment in established HF hampers disease progression and improves adverse electrophysiological and Ca2+ handling remodelling, attenuating the vulnerability to HF‐associated ventricular arrhythmias. Paricalcitol may emerge as a potential therapeutic option in the treatment of HF., This work was supported by the Spanish Ministry of Economy and Competitiveness (SAF2014‐57190R and SAF2017‐84777‐R), Instituto de Salud Carlos III (ISCIII) (PI17/01093 and PI17/01344), European Regional Developmentc Fund (FEDER), Sociedad Española de Cardiología (SEC) and Centro de Investigación Biomédica en Red Cardiovascular (CIBER‐CV), a network funded by ISCIII. M.F.‐V. is a Miguel Servet II researcher of ISCIII (MSII16/00047 Carlos III Health Institute). G.R.‐H. is a Miguel Servet I researcher of ISCIII (CP15/00129 Carlos III Health Institute). M.T. is a predoctoral fellow of the Spanish Ministry of Science, Innovation and Universities (Ministerio de Ciencia e Innovación) (FPU‐17/06135)., Peer reviewed